Targeting small ubiquitin‐related modifier‐specific protease 2 attenuates tumour progression and orchestrates the tumour immune microenvironment in diffuse large B‐cell lymphoma
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70187 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Xue Sheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Tumor Microenvironment, Cysteine Endopeptidases. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Department of Science and Technology of Shandong Province, Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China, Key Technology Research and Development Program of Shandong Province.
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) is a highly aggressive and heterogeneous haematological malignancy with poor outcomes, underscoring the need for novel therapeutic targets to improve remission rates. SUMO (small ubiquitin‐related modifier)‐specific protease 2 (SENP2) has been demonstrated to exert pleiotropic functions across diverse physiological processes and oncogenic transformation. Nevertheless, its precise function in DLBCL has rarely been investigated. Our research revealed that SENP2 was markedly overexpressed in DLBCL and its elevated levels were correlated with unfavourable prognosis. Furthermore, we constructed an integrative nomogram incorporating SENP2 expression and the International Prognostic Index score, which demonstrated robust predictive performance. Subsequently, SENP2 was validated to critically promote DLBCL cell proliferation both in vitro and in vivo. To investigate the underlying mechanisms, we performed RNA sequencing coupled with tumour infiltrating immune cells analysis, revealing that SENP2 knockout reduced myeloid‐derived suppressor cell accumulation while simultaneously enhancing both the infiltration and functional activation of CD8 + T cells. Finally, we performed virtual screening of Food and Drug Administration‐approved drugs against SENP2, followed by re‐docking analysis and identified four of the most promising candidates. Collectively, our findings characterized SENP2 as a novel prognostic biomarker and a promising therapeutic target in DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Shandong Key Laboratory of Hematological Diseases and Immune Microenvironment, Qilu Hospital of Shandong University, Jinan, Shandong, China.
ORCID-Profile: Chunyan Ji, Jingjing Ye
Förderung
- Department of Science and Technology of Shandong Province
- Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
- Key Technology Research and Development Program of Shandong Province
- Taishan Scholar Foundation of Shandong Province
- Natural Science Foundation of Shandong Province
- Shandong University
- National Natural Science Foundation of China
Zitieren
APA
Sheng, X., Wang, D., Li, S., Li, B., Luan, M., Han, X., Zhou, Q., Zhao, Z., Ji, C., Lu, F., & Ye, J. (2025). Targeting small ubiquitin‐related modifier‐specific protease 2 attenuates tumour progression and orchestrates the tumour immune microenvironment in diffuse large B‐cell lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.70187
Vancouver
Sheng X, Wang D, Li S, Li B, Luan M, Han X, et al. Targeting small ubiquitin‐related modifier‐specific protease 2 attenuates tumour progression and orchestrates the tumour immune microenvironment in diffuse large B‐cell lymphoma. British Journal of Haematology. 2025. doi:10.1111/bjh.70187
BibTeX
@article{Sheng2025,
author = {Sheng, Xue and Wang, Dongmei and Li, Shuying and Li, Boya and Luan, Mengfan and Han, Xiao and Zhou, Qirui and Zhao, Zhe and Ji, Chunyan and Lu, Fei and Ye, Jingjing},
title = {Targeting small ubiquitin‐related modifier‐specific protease 2 attenuates tumour progression and orchestrates the tumour immune microenvironment in diffuse large B‐cell lymphoma},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70187}
}
EUVIMED